Pre dicting D eterminants of A trial Fibrillation or Flutter for T herapy E lucidation in Patients at Risk for Thromboembolic Events (PREDATE AF) Study
Tài liệu tham khảo
Mozaffarian, 2015, Heart disease and stroke statistics—2015 update: a report from the American Heart Association, Circulation, 131, e29, 10.1161/CIR.0000000000000152
Lloyd-Jones, 2004, Lifetime risk for development of atrial fibrillation, Circulation, 110, 1042, 10.1161/01.CIR.0000140263.20897.42
Marini, 2005, Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study, Stroke, 36, 1115, 10.1161/01.STR.0000166053.83476.4a
Sanna, 2014, Cryptogenic stroke and underlying atrial fibrillation, N Engl J Med, 370, 2478, 10.1056/NEJMoa1313600
Leyden, 2013, Adelaide stroke incidence study, Stroke, 44, 1226, 10.1161/STROKEAHA.113.675140
Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039
Hart, 2007, Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation, Ann Intern Med, 146, 857, 10.7326/0003-4819-146-12-200706190-00007
Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561
Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638
Kirchhof, 2016, 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS, Eur Heart J, 37, 2893, 10.1093/eurheartj/ehw210
Kernan, 2014, Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack, Stroke, 45, 2160, 10.1161/STR.0000000000000024
Svennberg, 2015, Mass screening for untreated atrial fibrillation: the STROKESTOP study, Circulation, 131, 2176, 10.1161/CIRCULATIONAHA.114.014343
Engdahl, 2013, Stepwise screening of atrial fibrillation in a 75-year-old population, Circulation, 127, 930, 10.1161/CIRCULATIONAHA.112.126656
Schnabel, 2009, Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study, Lancet, 373, 739, 10.1016/S0140-6736(09)60443-8
Chamberlain, 2011, A clinical risk score for atrial fibrillation in a biracial prospective cohort, Am J Cardiol, 107, 85, 10.1016/j.amjcard.2010.08.049
Chyou, 2015, Individual and combined risk factors for incident atrial fibrillation and incident stroke: an analysis of 3 million at-risk US patients, J Am Heart Assoc, 4, e001723, 10.1161/JAHA.114.001723
Brunner, 2014, Clinical predictors of risk for atrial fibrillation: implications for diagnosis and monitoring, Mayo Clin Proc, 89, 1498, 10.1016/j.mayocp.2014.08.016
Saliba, 2016, Usefulness of CHADS2 and CHA2DS2-VASc scores in the prediction of new-onset atrial fibrillation: a population-based study, Am J Med, 129, 843, 10.1016/j.amjmed.2016.02.029
Chao, 2013, CHADS2 score and risk of new-onset atrial fibrillation: a nationwide cohort study in Taiwan, Int J Cardiol, 168, 1360, 10.1016/j.ijcard.2012.12.011
Hindricks, 2010, Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation: results of the XPECT trial, Circ Arrhythm Electrophysiol, 3, 141, 10.1161/CIRCEP.109.877852
Lip, 2010, Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation, Chest, 137, 263, 10.1378/chest.09-1584
Lowres, 2013, Screening to identify unknown atrial fibrillation: a systematic review, Thromb Haemost, 110, 213, 10.1160/TH13-02-0165
Healey, 2012, Subclinical atrial fibrillation and the risk of stroke, N Engl J Med, 366, 120, 10.1056/NEJMoa1105575
Reiffel JA. REVEAL AF: incidence of AF in high risk patients. In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT01727297. Cited October 21, 2016. Accessed January 3, 2017.
Healey JS, Alings M, Leong-Sit P, DeGraff J, Birnie D, Freericks M, Ha A, Verma A. Prevalence of sub-clinical atrial fibrillation using an implantable cardiac monitor in patients with cardiovascular risk factors: ASSERT II. Abstract presented at: American Heart Association’s Scientific Sessions 2016; November 15, 2016; New Orleans, LA.
Lowres, 2014, Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies: the SEARCH-AF study, Thromb Haemost, 111, 1167, 10.1160/TH14-03-0231
Cullen, 2013, Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry, Circ Cardiovasc Qual Outcomes, 6, 461, 10.1161/CIRCOUTCOMES.113.000127
Glotzer, 2009, The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study, Circ Arrhythm Electrophysiol, 2, 474, 10.1161/CIRCEP.109.849638
Boriani, 2014, Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project, Eur Heart J, 35, 508, 10.1093/eurheartj/eht491
Shanmugam, 2012, Detection of atrial high-rate events by continuous home monitoring: clinical significance in the heart failure–cardiac resynchronization therapy population, Europace, 14, 230, 10.1093/europace/eur293
Glotzer, 2003, Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke, Circulation, 107, 1614, 10.1161/01.CIR.0000057981.70380.45
Wolf, 1991, Atrial fibrillation as an independent risk factor for stroke: the Framingham Study, Stroke, 22, 983, 10.1161/01.STR.22.8.983
Healey J, Connolly S, Alings M, Lopes R. Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA). In: ClinicalTrials.gov. Bethesda, (MD: National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT01938248. Cited October 21, 2016. Accessed January 3, 2017.
Kirchhof P. Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes (NOAH). In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT02618577. Cited October 21, 2016. Accessed January 3, 2017.